Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
March 27 2015 - 8:00AM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, will hold its first-quarter 2015 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Tuesday, April 28. During the call, company executives
will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
http://www.merck.com/investors/events-and-presentations/home.html.
A replay of the webcast will be available at approximately 11:00
a.m. EDT on April 28 and will remain on the website for 12 months.
The sales and earnings news release and supplemental financial
disclosures also will be available in the Newsroom and Investor
sections of the company’s website at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (706) 758-9927 or (877) 381-5782 and using ID code
number 96680253. Members of the media are invited to monitor the
call by dialing (706) 758-9928 or (800) 399-7917 and using ID code
number 96680253. Journalists who wish to ask questions are
requested to contact a member of Merck’s Media Relations team at
the conclusion of the call.
About Merck
Today’s Merck is a global health care leader working to help the
world be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access
to health care through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com and connect
with us on Twitter, Facebook and YouTube.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of Merck’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in Merck’s 2014 Annual
Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
MerckMedia:Lainie Keller, (908) 236-5036Steven Cragle, (908)
740-1801orInvestor:Justin Holko, (908) 740-1879Joe Romanelli, (908)
740-1986
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024